Genome Therapeutics Corp. entered Into Its second human genomics alliance, this time with Wyeth-Ayerst Laboratories to develop therapeutics to prevent and treat osteoporosis. The collaboration could be worth $118 million for Genome Therapeutics, of Waltham, Mass., if the research program continues for Its full term and all milestones are met. The company also will receive royalties based on marketed products that come out of the collaboration.
The $118 million payment consists of an undisclosed up-front license fee, funding for a multiyear research program, as well as milestone payments. "This Is certainly our largest aggregate commercial biotech deal to date, said Robert …
Комментариев нет:
Отправить комментарий